8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 23, 2018

NEOGENOMICS, INC.

(Exact name of registrant as specified in its charter)

Nevada	001-35756	74-2897368
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

12701 Commonwealth Drive, Suite 9, Fort Myers, Florida	33913
(Address of principal executive offices)	(Zip Code)

(239) 768-0600

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

NeoGenomics, Inc. (the “Company”) today announced that it has entered into a material definitive agreement to acquire Genoptix, Inc., a leading clinical oncology laboratory specializing in hematology and solid tumor testing, based in Carlsbad, California. A copy of this press release is filed as Exhibit 99.1 hereto and incorporated herein by reference. In connection with this announcement, the Company has made available an Investor Presentation, which is attached to this Current Report on Form 8-K as Exhibit 99.2 and incorporated herein by reference. The Company presented this Investor Presentation during a scheduled web-cast and conference call to discuss the acquisition of Genoptix, Inc.

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits

99.1	Press Release of NeoGenomics, Inc. dated October 23, 2018.
99.2	Investor Presentation dated October 23, 2018.

Exhibit Index

Exhibit No.	Description
99.1	Press Release of NeoGenomics Inc., dated October 23, 2018.
99.2	Investor Presentation dated October 23, 2018.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NEOGENOMICS, INC.
By:	/s/ Sharon A. Virag
	Sharon A. Virag
	Chief Financial Officer
	October 23, 2018

EX-99.1

Exhibit 99.1

NeoGenomics Signs Definitive Agreement to Acquire Genoptix

Ft. Myers, Florida - October 23, 2018 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has entered into a definitive agreement to acquire Genoptix, Inc. for $125 million in cash and 1 million shares of NeoGenomics common stock. Genoptix is a leading clinical oncology laboratory, specializing in hematology and solid tumor testing, with an outstanding reputation and relationship with community oncologists across the United States. Genoptix’s strong capabilities complement NeoGenomics’ leadership position with hospitals and pathologists.

“The acquisition of Genoptix enhances NeoGenomics’ leadership in the oncology test market, significantly expanding our coverage of oncology practices, increasing our customer reach and leaving us better positioned for growth.” said Douglas M. VanOort, NeoGenomics’ Chairman and CEO. “With what we believe to be the most comprehensive oncology test menu in the country and reach across all distribution channels, the combined company will be uniquely positioned in the oncology test market.”

Benefits of the Transaction

• Advances expansion into community oncology practices. Genoptix has well-established relationships with community oncology practices, a sales force and pathologists that are experienced in serving oncologists, and customized reports that are considered to be the gold standard among community oncologists. Oncology practices are an important, and under-penetrated, channel for promoting NeoGenomics’ capabilities in next-generation sequencing and liquid biopsy.

• Leverages complementary services to create unprecedented offering in oncology testing market. NeoGenomics will draw on the best attributes from each company to improve the quality of service for all of our customers. Genoptix’s customers will benefit from NeoGenomics’ more comprehensive test offering, broad portfolio of managed care and GPO contracts, and national laboratory infrastructure. NeoGenomics’ customers will benefit from Genoptix customized consults and reports and extensive experience serving community oncologists. With deep relationships across all customer segments, NeoGenomics is positioned to better coordinate oncology testing between oncologists and pathologists within the community to improve patient care.

• Accelerates revenue and profit trajectory. The acquisition is expected to contribute $85 million of revenue and break-even EBITDA in year one, $25 million of cost synergies over time, and 25% EBITDA margin by the end of year three.

Advisors

Leerink Partners is acting as the exclusive advisor to NeoGenomics and K&L Gates LLP is serving as legal counsel. William Blair and Company is acting as the exclusive advisor to Genoptix, and Paul Hastings, LLP is serving as legal counsel.

Conference Call

The Company has scheduled a web-cast and conference call to discuss the acquisition on Tuesday, October 23, 2018 at 8:00 AM EDT. Interested investors should dial (877) 407-8035 (domestic) and (201) 689-8035 (international) at least five minutes prior to the call. A replay of the conference call will be available until 8:00 AM on October 30, 2018, and can be accessed by dialing (877) 481-4010 (domestic) and (919) 882-2331 (international). The playback conference ID Number is 39604. The web-cast may be accessed at http://www.investorcalendar.com/event/39604. An archive of the web-cast will be available until 08:00 AM on January 23, 2019.

About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Pharma Services division serves pharmaceutical clients in clinical trials and drug development.

Headquartered in Fort Myers, FL, NeoGenomics operates CLIA certified laboratories in Aliso Viejo and Fresno, California; Tampa and Fort Myers, Florida; Houston, Texas; Nashville, Tennessee and Rolle, Switzerland. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States. For additional information about NeoGenomics, visit http://neogenomics.com/.

Forward Looking Statements

Certain information contained in this press release constitutes forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ

2

materially from those anticipated in the forward-looking statements as the result of the Company’s ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan, as well as additional factors discussed under the heading “Risk Factors” and elsewhere in the Company’s Quarterly Report on Form 10-K filed with the SEC on March 13, 2018. As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. In addition, it is the Company’s practice to make information about the Company available by posting copies of its Company Overview Presentation from time to time on the Investor Relations section of its website at http://ir.neogenomics.com/.

Forward-looking statements represent the Company’s estimates only as of the date such statements are made (unless another date is indicated) and should not be relied upon as representing the Company’s estimates as of any subsequent date. While the Company may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its estimates change.

For further information, please contact:

NeoGenomics, Inc.

William Bonello

Chief Strategy and Corporate Development Officer

Director, Investor Relations

(239)690-4238 (w) (239)284-4314 (m)

bill.bonello@neogenomics.com

3

EX-99.2

NeoGenomics Acquisition of Genoptix October 23, 2018

Forward‐Looking Statements This presentation has been prepared by NeoGenomics, Inc. (“we,” ”us,” “our,” “NeoGenomics” or the “Company”) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither this presentation, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. This presentation contains “forward‐looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to business, operations, and financial conditions of the Company. Words such as, but not limited to, “look forward to,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “would,” “should” and “could,” and similar expressions or words, identify forward‐looking statements. Although the Company believes the expectations reflected in such forward‐looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Actual results could differ materially from those projected in the Company’s forward‐looking statements due to numerous known and unknown risks and uncertainties. All forward‐looking statements speak only as of the date of this presentation and are qualified in their entirety by this cautionary statement. The Company undertakes no obligation to revise or update this presentation to reflect events or circumstances after the date hereof. Non‐GAAP Adjusted EBITDA "Adjusted EBITDA" is defined by NeoGenomics as net income from continuing operations before: (i) interest expense, (ii) tax expense, (iii) depreciation and amortization expense, non‐cash stock‐based compensation expense, and if applicable in a reporting period, acquisition‐related transaction expenses (vi) non‐cash impairments of intangible assets (vii) debt financing costs (viii) and other significant non‐recurring or non‐operating (income) or expenses.

A New Standard in Oncology Testing NeoGenomics Well established as a leading  provider of oncology testing  for pathologists and hospitals Genoptix  Unprecedented reach to all customer segments  Broadest and deepest test menu in the Industry Outstanding reputation   Deep knowledge of community oncology practice and relationships with   Gold standard consults and reports community oncologists  Broad portfolio of managed care/GPO contracts   Highly efficient, oncology‐focused operations,  medical team, and sales force 3

Bends the Curve Potential Revenue  $500 • Incremental revenue of ~$85M • Pro form combined revenue of ~$350M  $400 • ~$25 million of cost synergies • ~25% EBITDA on incremental revenue  by end of year three  $300  $200 2018 2019 2020 2021 Pre Post Potential EBITDA  $110  $90  $70 Note: graphs and estimates are for illustrative purposes and   $50 do not represent company forecasts, with the exception of  2018, which is the mid‐point of previously issued guidance  $30 2018 2019 2020 2021 Pre Post 4

Genoptix Overview • Leading oncology‐focused lab • Outstanding reputation and relationship with community oncology practices  • Cases managed by specialized pathologists and hematopathologists • Experience with complex and challenging disease states • 170,000 test reports issued in 2017 • Located in Carlsbad, CA • Founded in 1999; IPO 2007; Acquired by Novartis 2011; Acquired by  Ampersand Capital, 1315 Capital and management in March of 2017 5

Expands Reach into Oncology Practices Significant opportunity Genoptix is well established in  for growth this market segment $2.5 billion revenue  40 person oncologist‐focused sales  opportunity force (5x larger than NeoGenomics’  current oncology team) >2,000 independent,  Customized reports specifically  community oncology  tailored for the oncologist  practices community Important channel for fastest  Specialized pathologists with years  growing tests (e.g., NGS and  of experience working directly with  Liquid Biopsy) oncologists 6

Leverages Best Offerings MANAGED CARE CUSTOMIZED  EXTENSIVE  PHARMA  NATIONAL  AND GPO  REPORTING TEST MENU SERVICES FOOTPRINT CONTRACTS  NeoGenomics’ test  Synergistic  With operations on  NeoGenomics  Genoptix has a  menu includes many  pharma services  both coasts,  has a broad  suite of  tests that Genoptix business drives  NeoGenomics will  portfolio of  customized  does not currently  be able to improve  access to  contracts in  reporting tools  offer to its customers  turn‐around time  • Broader portfolio  companion  for Genoptix which  that are  of NGS tests diagnostics customers Genoptix does  considered the  • 10‐color flow not participate gold standard  • Greater number of  among  IHC tests oncologists • Solid tumor  pathology   7

COMPASS® and CHART® COMPASS: comprehensive, hematopathologist‐directed,  integrated assessment report • Customized workflow on each patient case to provide a  disease‐specific evaluation based on up‐to‐date guidelines • Actionable diagnosis in a one‐page correlation report • Consultation with assigned hematopathologist available on  every case • Notification of acute cases and unexpected diagnoses within  24 hours • Real‐time electronic reporting with Genoptix Online,  powered by eCOMPASS™ • Review of challenging cases and presentation of tumor  conferences with a Genoptix Hematopathologist through  eRounds CHART: a longitudinal report including a consultative review and correlation  with relevant prior findings by a Genoptix Hematopathologist, used to: • Monitor response to therapy • Determine disease progression • Evaluate clonal evolution • Assess residual disease 8

Creates Innovative Value Proposition NEOGENOMICS • Can provide both technical  and professional services  (including customized  consults and reports) to  oncologist, when preferred • ONCOLOGIST Can provide “tech‐only”  services to pathologist when  Expanded referral  preferred by oncologist options with access to  both NeoGenomics and  affiliated community‐ PATHOLOGIST based pathologists Opportunity for increased  referrals from community  oncologists leveraging  NeoGenomics’ “tech‐only”  offering 9

Raises the Bar • Significantly expands reach into oncology practices • Creates unique value proposition for oncologists,  pathologists, hospitals, payors and patients  • Enhances and leverages combined product offering • Increases opportunity for coordination between  oncologists and pathologists within the community  • Accelerates revenue and profit trajectory 10

© 2018 NeoGenomics Laboratories, Inc. All rights reserved. All other trademarks are the property of their respective owners.